Marine Lectins 2nd Edition

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (1 March 2024) | Viewed by 1186

Special Issue Editors


E-Mail Website
Guest Editor
G. B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of Russian Academy of Sciences, Vladivostok, Russia
Interests: lectins; glycobiology; marine invertebrates; glycosylation; antitumor activity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
G. B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of Russian Academy of Sciences, Vladivostok, Russia
Interests: lectins; oncofetal antigens; glycobiology; biological activity; immunity of marine invertebrates
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,                

The rapid development of research in the field of glycobiology has revealed the key role of lectins in intercellular interactions, which has dramatically increased interest in these molecules. Marine biological resources are widely used as sources for obtaining new physiologically active substances and objects for fundamental and applied biomedical research. More and more lectins are being isolated from marine organisms. Lectins from marine sources are structurally diverse, and their unique properties hold potential for biomedical applications. This is due to the fact that marine organisms live in a very demanding, competitive and aggressive environment that requires the production of rather specific and active molecules. Most research is focused on their use as antibacterial, antifungal, antiviral, anticancer, and anti-inflammatory agents. The purpose of this Special Issue is to summarize the latest data on the structure, biological properties and application opportunities of marine lectins.

Dr. Oleg V. Chernikov
Dr. Irina V. Chikalovets
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine lectins
  • glycobiology
  • marine organisms
  • lectin structure
  • lectin function
  • lectin activity
  • lectin application
  • glycosylation
  • carbohydrate-binding activity

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2231 KiB  
Article
ROS Induced by Aphrocallistes vastus Lectin Enhance Oncolytic Vaccinia Virus Replication and Induce Apoptosis in Hepatocellular Carcinoma Cells
by Yanan Zhang, Ying Zhu, Gaohui Jiang, Ke Chen, Guohui Zhang, Kan Chen, Ting Ye, Yanrong Zhou and Gongchu Li
Mar. Drugs 2024, 22(7), 307; https://doi.org/10.3390/md22070307 - 30 Jun 2024
Viewed by 940
Abstract
Oncolytic virotherapy is expected to provide a new treatment strategy for cancer. Aphrocallistes vastus lectin (AVL) is a Ca2+-dependent lectin receptor containing the conserved domain of C-type lectin and the hydrophobic N-terminal region, which can bind to the bird’s nest glycoprotein [...] Read more.
Oncolytic virotherapy is expected to provide a new treatment strategy for cancer. Aphrocallistes vastus lectin (AVL) is a Ca2+-dependent lectin receptor containing the conserved domain of C-type lectin and the hydrophobic N-terminal region, which can bind to the bird’s nest glycoprotein and D-galactose. Our previous studies suggested that the oncolytic vaccinia virus (oncoVV) armed with the AVL gene exerted remarkable replication and antitumor effects in vitro and in vivo. In this study, we found that oncoVV-AVL may reprogram the metabolism of hepatocellular carcinoma cells to promote ROS, and elevated ROS subsequently promoted viral replication and induced apoptosis. This study will provide a new theoretical basis for the application of oncoVV-AVL in liver cancer. Full article
(This article belongs to the Special Issue Marine Lectins 2nd Edition)
Show Figures

Figure 1

Back to TopTop